Revenue, 2025

USD 6.81 Billion

Forecast, 2035

USD 137.36 Billion

CAGR, 2026-2035

35.05%

Report Coverage

Global

Oral GLP-1 Market Trends for 2026

The oral GLP-1 market size in 2025 was US$ 6.81 billion, expected to grow to US$ 9.19 billion in 2026 and further to US$ 137.36 billion by 2035, backed by a robust CAGR of 35.05% between 2026 and 2035.

The oral GLP-1 market is witnessing strong growth, driven by rising prevalence of type 2 diabetes and obesity, increasing patient preference for oral therapies, and continuous pharmaceutical innovations. North America leads the market due to advanced healthcare infrastructure, high patient awareness, supportive reimbursement policies, and the strong presence of key players like Novo Nordisk and Eli Lilly, ensuring rapid adoption of oral GLP-1 therapies.

Key Takeaways

• Oral GLP-1 market to crossed USD 9.19 billion by 2026.
• Market projected at USD 137.36 billion by 2035.
• CAGR of 35.05% expected in between 2026 to 2035.
• North America held a major revenue share of 46% of the oral GLP-1 market in 2025.
• Asia-Pacific is expected to witness the fastest growth during the predicted timeframe.
• By drug type, the oral peptide GLP-1 agonists segment registered its dominance over the global market with a share of approximately 63% in 2025.
• By drug type, the small-molecule non-peptide GLP-1 agonists segment is expected to grow with the highest CAGR in the market during the studied years.
• By molecule, the semaglutide segment held a dominant presence in the market with a share of 71% in 2025.
• By molecule, the orforglipron segment is expected to witness the fastest growth in the market over the forecast period.
• By distribution channel, the hospital & specialty clinics segment held a dominant presence in the Oral GLP-1 market with a share of 52% in 2025.
• By distribution channel, the online pharmacies segment is expected to witness the fastest growth in the market over the forecast period.
• By end user, the diabetic population segment registered its dominance over the global market with a share of 64% in 2025.
• By end user, the obese/overweight individuals segment is expected to grow with the highest CAGR in the market during the studied years.

What is meant by Oral GLP-1?

The oral GLP-1 market is driven by the rising prevalence of type 2 diabetes and obesity, increasing demand for convenient oral treatments, and growing awareness of effective diabetes management options. Patients prefer oral formulations over injectable therapies, boosting adoption and adherence. Oral GLP-1 refers to a class of medications that mimic the action of the naturally occurring hormone GLP-1, which regulates blood sugar levels by stimulating insulin secretion, suppressing glucagon release, and slowing gastric emptying. These therapies improve glycemic control and aid in weight management, offering a less invasive alternative to injectable GLP-1 treatments while enhancing patient convenience and compliance.

How is AI Revolutionizing the Market?

AI is revolutionizing the oral GLP-1 market by accelerating drug discovery and optimizing formulations, moving beyond traditional injections. Deep learning tools are designing stable, novel peptides that offer superior efficacy and extended half-lives compared to current options. These computational platforms analyze vast datasets to enhance oral bioavailability and predict treatment responses. Key players like Eli Lilly and Novo Nordisk utilize AI to expedite clinical trials for new oral molecules and identify candidates with lower gastrointestinal side effects.

Market Outlook

Industry Growth Overview:

• The Oral GLP-1 market is experiencing robust growth due to rising type 2 diabetes and obesity prevalence, increasing patient preference for oral therapies, continuous pharmaceutical innovations, and supportive healthcare infrastructure, enabling wider adoption and improved treatment adherence across global populations.
• Global Expansion: The Oral GLP-1 market is expanding globally, with North America leading due to advanced healthcare systems and high patient awareness. Europe shows steady growth driven by regulatory support and diabetes prevalence, while Asia Pacific presents emerging opportunities fueled by increasing type 2 diabetes cases, rising healthcare access, and growing patient adoption.
• Major Investors: The market attracts significant investment from both private and public sectors. Key pharmaceutical companies like Novo Nordisk, Eli Lilly, and AstraZeneca are major investors, funding research, clinical trials, and product launches. Additionally, venture capital and sustainability-focused healthcare funds are providing financial support for innovative oral GLP-1 formulations. Government initiatives promoting diabetes care, obesity management, and healthcare accessibility further bolster investment. Collectively, these investments accelerate R&D, expand manufacturing capabilities, and enhance global distribution, driving growth and innovation in the Oral GLP-1 market.

Oral GLP-1 Market Trends

• Rising Preference for Oral Therapies: Patients increasingly prefer oral GLP-1 medications over injectable forms due to ease of use, improved adherence, and enhanced quality of life, driving market demand globally.
• Expansion into Obesity Management: Beyond diabetes, oral GLP-1s are being adopted for weight management, with clinical trials demonstrating efficacy in reducing body weight, broadening therapeutic applications.
• Pharmaceutical Innovation and New Launches: Companies are developing formulations with improved bioavailability, extended-release profiles, and combination therapies, supporting better patient outcomes and competitive differentiation.
• Growing Awareness and Healthcare Programs: Awareness campaigns and diabetes management programs are increasing patient knowledge, encouraging adoption of oral GLP-1 therapies, and promoting early intervention.
• Strategic Collaborations and Partnerships: Biotech startups and established pharmaceutical firms are forming alliances to accelerate R&D, enhance production capabilities, and expand global market reach.

Advancements in Oral GLP-1

The Oral GLP-1 therapy landscape has seen significant advancements in 2025, focusing on improved bioavailability, enhanced efficacy, and patient convenience. Novel oral formulations now utilize absorption enhancers and protective coatings to optimize gastrointestinal uptake. Extended-release and combination therapies are being developed to provide sustained glucose control and weight management. Key pharmaceutical players, including Novo Nordisk and Eli Lilly, are conducting innovative clinical trials, while strategic collaborations with biotech startups accelerate R&D. These developments collectively enhance therapeutic outcomes, patient adherence, and global accessibility of oral GLP-1 treatments.

Executive Summary Table

Segmental Insights

By Drug Type

Explanation

• Oral Peptide GLP-1 Agonists improve glucose control and hold 63% and dominate due to high efficacy, established clinical use, and strong patient adoption.
• Small-Molecule Non-Peptide GLP-1 Agonists offer oral alternatives and capture 37% but do not dominate as they are newer, with limited clinical adoption and data.

Which Drug Type Segment Dominated the Oral GLP-1 Market?

The oral peptide GLP-1 agonists segment dominates the market with a share of 63% due to its proven efficacy in controlling blood glucose levels and supporting weight management. Patient preference for non-invasive oral administration over injections enhances adherence and convenience. Strong R&D focus, successful clinical trials, and the presence of established pharmaceutical players like Novo Nordisk and Eli Lilly further reinforce its leading position in the market.

The small-molecule non-peptide GLP-1 agonists segment is estimated to be the fastest-growing in the global oral GLP-1 market due to its high oral bioavailability, ease of manufacturing, and potential for cost-effective production. These molecules offer improved patient convenience, reduced injection dependency, and the ability to combine with other therapies. Ongoing clinical trials and strong pharmaceutical investments are accelerating adoption and market expansion.

By Molecule

Explanation

• Semaglutide (Oral Formulation) effectively manages glucose and holds 71% and dominates due to strong clinical evidence, brand recognition, and widespread adoption.
• Danuglipron offers oral GLP-1 therapy and captures 10% but does not dominate due to limited clinical use and early-stage adoption.
• Orforglipron provides alternative oral GLP-1 treatment and holds 12% but does not dominate as it is still emerging in the market.
• Lotiglipron delivers oral GLP-1 benefits and represents 7% but does not dominate due to minimal market presence and early development stage.
• Other Emerging Candidates explore new therapies and hold 0% and do not dominate as they are in preclinical or conceptual stages.

Which Molecule Segment Led the Oral GLP-1 Market?

The semaglutide segment dominates the market with a share of 71% due to its proven efficacy in controlling blood glucose and promoting weight loss. Strong clinical trial results, widespread physician adoption, and high patient preference for oral administration enhance its market leadership. Additionally, robust marketing, strategic partnerships, and continuous product innovation by key players like Novo Nordisk reinforce semaglutide’s dominant position.

The Orforglipron segment is the fastest-growing in the oral GLP-1 market due to its innovative small-molecule, non-peptide oral formulation, which eliminates the need for injections and enhances patient convenience. High oral bioavailability, strong efficacy in weight reduction and glycemic control, and favorable safety profiles accelerate adoption. Ongoing clinical success, regulatory submissions, and backing by Eli Lilly further drive rapid market growth, making Orforglipron a leading therapy in both obesity management and type 2 diabetes treatment.

By Distribution Channel

Explanation

• Hospital & Specialty Clinics provide direct patient care and hold 52% and dominate due to established trust, prescriptions, and high patient traffic.
• Retail Pharmacies distribute medications and capture 30% but do not dominate as they rely on prescriptions and have limited clinical support.
• Online Pharmacies offer digital access to treatments and hold 18% but do not dominate due to regulatory hurdles and lower consumer trust.

What Made Hospital & Specialty Clinics the Dominant Segment in the Oral GLP-1 Market?

The hospital & specialty clinics segment dominates the market with a share of approximately 52% due to the availability of advanced diagnostic facilities, skilled healthcare professionals, and access to novel diabetes and obesity treatments. These centers are primary points for prescribing and monitoring oral GLP-1 therapies, ensuring patient safety and treatment adherence. Additionally, growing hospital-based clinical research and collaborations with pharmaceutical companies enhance early drug access and drive higher adoption rates.

The online pharmacies segment is anticipated to be the fastest-growing segment in the market due to increasing digital healthcare adoption, convenience in medicine delivery, and rising telemedicine integration. Patients prefer online platforms for accessibility, privacy, and cost-effectiveness. Moreover, partnerships between e-pharmacy platforms and drug manufacturers in 2025 have accelerated the availability of oral GLP-1 therapies across wider geographies.

By End User

Explanation

• Diabetic Population requires glucose management and holds 64% and dominates due to high disease prevalence and continuous treatment needs.
• Obese/Overweight Individuals seek weight and metabolic management and capture 36% but do not dominate as adoption is limited to lifestyle-focused interventions.

Which End-User Segment Led the Oral GLP-1 Market?

The diabetic population segment dominates the market with a share of 64% due to the rising prevalence of type 2 diabetes worldwide and increasing awareness of effective glucose control therapies. The growing preference for oral GLP-1 drugs over injectables enhances patient compliance. Additionally, government health programs and clinical advancements in 2025 have strengthened treatment accessibility and adoption among diabetic patients.

The obese/overweight individuals segment is anticipated to be the fastest-growing in the global oral GLP-1 market due to the rising global obesity rates and growing awareness of weight management therapies. In 2025, increased clinical success of oral GLP-1 drugs for weight loss and broader approvals by regulatory bodies have driven demand among individuals seeking non-invasive, effective obesity treatment options.

Regional Analysis

Which Factors Contribute to North America’s Dominance in the Oral GLP-1 Market?

North America dominates the global market with a share of 46% due to the high prevalence of type 2 diabetes and obesity, advanced healthcare infrastructure, and strong presence of major pharmaceutical companies like Novo Nordisk and Eli Lilly. Additionally, the rapid adoption of innovative oral GLP-1 therapies and favorable regulatory support drive market growth across the U.S. and Canada.

What are the Trends in the U.S. Market?

The U.S. leads the oral GLP-1 market due to a large diabetic and obese population, strong R&D capabilities, and rapid adoption of innovative therapies like oral semaglutide. Supportive FDA approvals and increasing physician preference for convenient oral alternatives further strengthen the country’s market dominance.

As of 2024, approximately 11.6% of the U.S. population has diabetes, including those undiagnosed. Furthermore, around 30.7% of adults are overweight, and over 42.4% have obesity. A staggering 97.6 million Americans also have prediabetes. 

Which Factors make the Asia Pacific Region the fastest-growing region?

The Asia-Pacific region is the fastest-growing oral GLP-1 market due to the rapidly increasing prevalence of diabetes and obesity, particularly in China, India, and Japan. Rising healthcare expenditure, growing awareness of advanced oral antidiabetic drugs, and improving access to healthcare infrastructure are key contributors. Additionally, the region is witnessing strategic collaborations between global pharmaceutical companies and local firms, along with government initiatives to manage lifestyle diseases, which collectively drive strong demand for oral GLP-1 treatments across Asia-Pacific.

What are the Ongoing Trends in the China Market?

China’s Oral GLP-1 market is expanding rapidly in 2025 due to the country’s rising diabetes and obesity rates, with nearly 148 million diabetic adults and over 60% of the population overweight or obese, creating strong demand for effective glucose-lowering and weight-management therapies. In February 2025, the National Medical Products Administration (NMPA) approved Innogen’s ultra-long-acting GLP-1 injection for type 2 diabetes, signaling growing government and regulatory support for GLP-1 innovation and boosting industry confidence.

In August 2025, Hengrui Medicine advanced its oral small-molecule GLP-1 candidate HRS-7535 into late-stage development, emphasizing local capability in producing affordable oral treatments that improve patient compliance. Additionally, in June 2024, Huadong Medicine’s Sinopharm Huadong received U.S. trial approval for HDM1002, an oral GLP-1 full agonist, demonstrating China’s expanding international research collaborations and technological strength. These developments, combined with active investment in biopharmaceutical R&D, are strongly propelling the growth of China’s oral GLP-1 market.

What are the Trends in the India Market?

India has over 77 million adults with diabetes as of 2025.  Rising case numbers expand the patient base needing effective, easier treatments like oral GLP-1 therapies. Also, needle phobia and injection inconvenience drive preference for pills.  Moreover, recent launches such as Novo Nordisk’s oral semaglutide in India provide more accessible GLP-1 options.  Government policies supporting local manufacturing and incentives for drug makers also help lower costs and widen availability. 

How Big is the Opportunity for the Growth of the Europe Oral GLP-1 Market?

Europe is growing notably in the oral GLP-1 market due to a high diabetes burden: about 66 million adults in Europe have diabetes, and nearly 34% remain undiagnosed.  Strong national healthcare systems in Germany, the UK, and France support broad access and reimbursement for GLP-1 therapies. Regulatory backing, rising obesity rates, aging populations, and public health programs emphasizing non-injectable treatments are increasing the acceptance of oral GLP-1s. These dynamics, alongside pharmaceutical innovation and awareness campaigns, are accelerating Europe’s market expansion.

Rising Cases of Diabetes and Obesity are Driving the UK

As of 2024, there are 4.6 million diagnosed diabetic cases in the UK, plus an estimated 1.3 million undiagnosed. In England, 60    % of adults are overweight or obese, with nearly 30% considered obese. These figures contribute to rising health challenges.

Value Chain Analysis

R&D

The R&D phase in the oral GLP-1 market begins with target identification and lead discovery, where pharmaceutical and biotech companies such as Novo Nordisk and Eli Lilly focus on developing peptide or small-molecule GLP-1 agonists. This is followed by preclinical studies to assess pharmacology and toxicity, along with formulation development to enhance oral bioavailability through absorption-enhancement systems. Next, companies work on process development and scale-up, supported by Contract Development and Manufacturing Organizations (CDMOs) and academic collaborations. Finally, detailed chemistry, manufacturing, and control (CMC) documentation is prepared to meet regulatory submission requirements.

Organizations involved: pharmaceutical R&D teams (Novo Nordisk, Eli Lilly), biotech startups, academic labs, specialized formulation companies, contract research organizations (CROs) for preclinical work, and CMC/CDMO partners for scale-up.

Clinical Trials & Approval

The clinical development phase begins with Investigational New Drug (IND) submissions and proceeds through Phase I trials for safety and pharmacokinetics, Phase II for dose optimization and early efficacy, and Phase III for large-scale confirmation of therapeutic benefits. Once completed, companies compile data for regulatory submission to agencies such as the U.S. FDA, European Medicines Agency (EMA), Japan’s PMDA, or India’s CDSCO. After review and approval, the drug is launched into the market, followed by post-marketing surveillance to ensure long-term safety and efficacy. Key players in this phase include major pharma sponsors, Contract Research Organizations (CROs), clinical trial networks, and regulatory consultants.

Organizations involved: sponsor pharma/biotech, clinical research organizations (CROs) running trials, clinical sites and investigators, central labs, data monitoring boards, regulatory agencies (FDA, EMA, PMDA, NMPA, CDSCO), and regulatory consultants for dossier preparation

Patient Support & Services

After approval, the focus shifts to market access, pricing, and reimbursement negotiations with healthcare payers. Pharmaceutical companies then launch education programs for healthcare professionals and patient onboarding initiatives to ensure proper prescription and adherence. Patient support services include telehealth assistance, reminder applications, affordability programs, and co-pay support to improve therapy compliance. These activities are carried out by specialty clinics, retail and online pharmacies, pharma patient-support divisions, digital health partners, and patient advocacy groups. Ongoing real-world monitoring and outcomes assessments help optimize treatment benefits and sustain market growth.

Organizations involved: payers/insurers, hospital specialty clinics, retail and online pharmacies, patient advocacy groups, specialty pharmacies, telemedicine providers, pharma patient-support teams, digital health vendors (adherence apps, remote monitoring), and third-party benefits managers.

SWOT Analysis

Strengths

• Oral GLP-1 medications like Rybelsus offer non-invasive daily pill options, greatly improving patient adherence compared to injectable alternatives.
• Besides helping with diabetes, oral GLP-1s are effective for long-term weight management and are being studied for their ability to lower cardiovascular risks and tackle metabolic issues.

Weaknesses

• The high costs of these treatments make them less accessible for patients and require complex, ongoing negotiations with insurance companies.
• Oral biologics struggle to achieve the same absorption rates as injectable forms.

Opportunities

• The development of stronger oral medications, along with the potential for oral dual or triple agonists that combine GLP-1, GIP, and GCG, offers significant growth potential.
• With over a billion people worldwide considered obese, the market for weight management products is enormous and still largely untapped.

Threats

• The entry of various pharmaceutical companies, such as Eli Lilly and Amgen, along with the rise of next-generation treatments, threatens the market share of established players.
• Strict FDA and EMA approval processes for safety and effectiveness can lead to delays in bringing products to market.

Top Vendors in Oral GLP-1 Market & Their Offerings:

Novo Nordisk

Offers: Rybelsus (oral semaglutide) for type 2 diabetes, Ozempic (injectable), Wegovy (higher-dose semaglutide for obesity), among its portfolio. 

Focus: Improving formulations, patient access, and expanding indications.

Eli Lilly

Offers: Mounjaro (tirzepatide) for diabetes, Zepbound for obesity, and developing Orforglipron, an oral GLP-1 agonist. 

Focus: Dual-agonist therapies, weight loss efficacy, and better adherence via oral options. 

Pfizer

Offers / Pipeline: Working on oral GLP-1 analogs; pushing innovations in drug delivery and trials.

AstraZeneca

Offers / Pipeline: Products like Bydureon (exenatide extended-release) and oral candidates (e.g., AZD5004) in development. 

Sanofi

Position: Has historically worked in the GLP-1 space (with drugs like liraglutide, lixisenatide) and is now focusing on metabolic disease innovation and new partnerships.

Top Companies in the Oral GLP-1 Market

• Novo Nordisk
• Eli Lilly
• AstraZeneca
• Roche
• Viking Therapeutics
• Merck
• Structure Therapeutics
• Verdiva Bio
• Sun Pharma
• Pfizer
• Zealand Pharma
• Rani Therapeutics
• Hengrui Medicine
• Altimmune
• Eccogene

Recent Development in the Oral GLP-1 Market

• In April 2025, Eli Lilly announced that Orforglipron, their oral GLP-1 receptor agonist, demonstrated statistically significant reductions in A1C levels, averaging between 1.3% and 1.6% across various doses. In August 2025, Lilly reported that Orforglipron achieved up to 18.4% weight loss in patients at the highest dose, with 36 mg, compared to 2.8% in the placebo group.  Lilly is preparing to submit regulatory filings for Orforglipron in 2026, aiming for potential market entry in 2027.
• In February 2025, Novo Nordisk submitted a New Drug Application (NDA) to the FDA for an oral formulation of Wegovy (semaglutide) for weight loss. The FDA's review is expected to be completed by the end of 2025.
• In September 2025, Novo Nordisk published data showing that their oral semaglutide 25 mg formulation led to an average weight loss of 16.6% in patients with obesity over a 64-week period.
• On August 28, 2025, Teva Pharmaceuticals received FDA approval and launched a generic version of Saxenda (liraglutide injection) in the U.S., making it the first generic GLP-1 drug indicated for weight loss. 

Segments Covered in the Report

By Drug Type

• Oral Peptide GLP-1 Agonists
• Small-Molecule Non-Peptide GLP-1 Agonists

By Molecule

• Semaglutide (Oral Formulation)
• Danuglipron
• Orforglipron
• Lotiglipron
• Other Emerging Candidates (GLP-1/GIP dual or non-peptide analogs)

By Distribution Channel

• Hospital & Specialty Clinics
• Retail Pharmacies
• Online Pharmacies

By End User

• Diabetic Population
• Obese / Overweight Individuals
• Cardiovascular-Risk Patients

By Region

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • U.K.
  • France
  • Germany
  • Italy
  • Spain
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • South-East Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Argentina
  • Rest of Latin America
• Middle East & Africa
  • GCC Countries
  • South Africa 
  • Rest of Middle East & Africa